Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.

Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, Kato I, Yokokura T.

Cancer Chemother Pharmacol. 2008 Apr;61(4):595-605. Epub 2007 Jun 5.

PMID:
17549477
2.

Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.

Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, Uchida K, Onoue M, Yokokura T.

Cancer Chemother Pharmacol. 2011 Jan;67(1):201-13. doi: 10.1007/s00280-010-1310-4. Epub 2010 Mar 31.

PMID:
20354702
3.

The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.

Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, Smith PC.

J Pharmacol Exp Ther. 2007 Jan;320(1):29-37. Epub 2006 Sep 26.

4.

Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.

Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T.

Cancer Chemother Pharmacol. 2000;46(3):211-20.

PMID:
11021738
5.

Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.

Wang SW, Kulkarni KH, Tang L, Wang JR, Yin T, Daidoji T, Yokota H, Hu M.

J Pharmacol Exp Ther. 2009 Jun;329(3):1023-31. doi: 10.1124/jpet.108.147371. Epub 2009 Mar 5.

7.

Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T.

Cancer Chemother Pharmacol. 2003 Nov;52(5):349-60. Epub 2003 Aug 6.

PMID:
12904895
8.

Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M, Zhou SF.

Curr Drug Metab. 2006 May;7(4):431-55.

PMID:
16724931
9.

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.

Cancer Chemother Pharmacol. 2006 Oct;58(4):494-503. Epub 2006 Jan 25.

PMID:
16437251
10.

Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia.

Kotal P, Van der Veere CN, Sinaasappel M, Elferink RO, Vítek L, Brodanová M, Jansen PL, Fevery J.

Pediatr Res. 1997 Aug;42(2):195-200.

PMID:
9262222
11.

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T.

Cancer Res. 1996 Aug 15;56(16):3752-7.

12.

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T.

Cancer Chemother Pharmacol. 1998;42(4):280-6.

PMID:
9744772
13.

Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation.

Seppen J, Tada K, Ottenhoff R, Sengupta K, Chowdhury NR, Chowdhury JR, Bosma PJ, Oude Elferink RP.

Hum Gene Ther. 1997 Jan 1;8(1):27-36.

PMID:
8989992
14.

Gunn rat: a model for inherited deficiency of bilirubin glucuronidation.

Chowdhury JR, Kondapalli R, Chowdhury NR.

Adv Vet Sci Comp Med. 1993;37:149-73. Review.

PMID:
8273513
15.

Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.

Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, Ryuge S, Wada M, Onoda S, Yanaihara T, Yokoba M, Mitsufuji H, Nishii Y, Fukui T, Masuda N.

Oncol Rep. 2008 Oct;20(4):727-30.

PMID:
18813810
17.

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y.

Ther Drug Monit. 2002 Feb;24(1):111-6.

PMID:
11805731
18.

Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.

Hidaka M, Yamasaki K, Okumura M, Ogikubo T, Iwakiri T, Setoguchi N, Nishida K, Nagai K, Ikenoue T, Arimori K.

Cancer Chemother Pharmacol. 2007 Feb;59(3):321-8. Epub 2006 Jun 13.

PMID:
16770581
20.

Biliary excretion of irinotecan and its metabolites.

Itoh T, Takemoto I, Itagaki S, Sasaki K, Hirano T, Iseki K.

J Pharm Pharm Sci. 2004 Jan 23;7(1):13-8.

Supplemental Content

Support Center